- Home
- DXR vs CELU Comparison
DXR vs CELU Comparison
Compare DXR & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- CELU
- Stock Information
- Founded
- DXR 1970
- CELU 2016
- Country
- DXR United States
- CELU United States
- Employees
- DXR N/A
- CELU N/A
- Industry
- DXR Medical/Dental Instruments
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- DXR Health Care
- CELU Health Care
- Exchange
- DXR Nasdaq
- CELU Nasdaq
- Market Cap
- DXR 36.4M
- CELU 37.7M
- IPO Year
- DXR N/A
- CELU N/A
- Fundamental
- Price
- DXR $7.30
- CELU $2.02
- Analyst Decision
- DXR Strong Buy
- CELU
- Analyst Count
- DXR 1
- CELU 0
- Target Price
- DXR $25.00
- CELU N/A
- AVG Volume (30 Days)
- DXR 4.8K
- CELU 72.0K
- Earning Date
- DXR 01-01-0001
- CELU 05-08-2025
- Dividend Yield
- DXR N/A
- CELU N/A
- EPS Growth
- DXR 86.16
- CELU N/A
- EPS
- DXR 0.11
- CELU N/A
- Revenue
- DXR $119,714.00
- CELU $54,220,000.00
- Revenue This Year
- DXR N/A
- CELU $23.29
- Revenue Next Year
- DXR N/A
- CELU N/A
- P/E Ratio
- DXR $66.24
- CELU N/A
- Revenue Growth
- DXR N/A
- CELU 138.11
- 52 Week Low
- DXR $6.55
- CELU $1.00
- 52 Week High
- DXR $10.00
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- DXR 44.11
- CELU 65.45
- Support Level
- DXR $7.19
- CELU $1.51
- Resistance Level
- DXR $7.74
- CELU $2.20
- Average True Range (ATR)
- DXR 0.41
- CELU 0.20
- MACD
- DXR -0.02
- CELU 0.04
- Stochastic Oscillator
- DXR 27.40
- CELU 75.27
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.